ProQR Therapeutics N.V. (PRQR) |
|
2.89 0.04 (1.4%)
|
01-27 16:00 |
|
Open: |
2.82 |
Pre. Close: |
2.85 |
|
High:
|
2.97 |
Low:
|
2.785 |
|
Volume:
|
1,008,438 |
Market Cap:
|
206(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:47:14 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 4.41 One year: 5.15 |
| Support: |
Support1: 2.41  Support2: 1.56 |
| Resistance: |
Resistance1: 3.77 Resistance2: 4.41 |
| Pivot: |
3.13 |
| Moving Average: |
MA(5): 2.78 MA(20): 3.21
MA(100): 1.54 MA(250): 1.23 |
| MACD: |
MACD(12,26): 0.1 Signal(9): 0.2 |
| Stochastic oscillator: |
%K(14,3): 31.5 %D(3): 27.5 |
| RSI: |
RSI(14): 52.1 |
| 52-week: |
High: 6.15 Low: 0.52 |
| Average Vol(K): |
3-Month: 3,080 (K) 10-Days: 1,764 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PRQR ] has closed above bottom band by 32.5%. Bollinger Bands are 107% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.97 - 2.99 |
2.99 - 3 |
|
Low:
|
2.76 - 2.77 |
2.77 - 2.78 |
|
Close:
|
2.87 - 2.89 |
2.89 - 2.91 |
|
Company Description |
|
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands. |
Headline News |
Sun, 29 Jan 2023
ProQR Therapeutics (NASDAQ:PRQR) Receives Average ... - MarketBeat
Fri, 27 Jan 2023
ProQR Therapeutics N.V. (NASDAQ:PRQR) Up Almost 5.17% In 1 ... - Marketing Sentinel
Thu, 26 Jan 2023
Can ProQR Therapeutics NV (PRQR) Stock Rise to the Top of Healthcare Sector Thursday? - InvestorsObserver
Thu, 19 Jan 2023
Institutions along with individual investors who hold considerable shares inProQR Therapeutics N.V. (NASDAQ:PRQR) come under pressure; lose 11% of holdings value - Simply Wall St
Wed, 18 Jan 2023
LLY: 4 Pharma Stocks You Shouldn't Think Twice About Buying in ... - StockNews.com
Wed, 11 Jan 2023
ProQR Therapeutics (NASDAQ:PRQR) Lifted to "Hold" at StockNews ... - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
71 (M) |
|
% Held by Insiders
|
5.721e+007 (%) |
|
% Held by Institutions
|
20.8 (%) |
|
Shares Short
|
686 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-6.6e+007 |
|
EPS Est Next Qtl
|
-0.52 |
|
EPS Est This Year
|
-2.11 |
|
EPS Est Next Year
|
-1.75 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
694.6 |
|
Return on Equity (ttm)
|
-26.3 |
|
Qtrly Rev. Growth
|
3.93e+006 |
|
Gross Profit (p.s.)
|
-50.46 |
|
Sales Per Share
|
-338.69 |
|
EBITDA (p.s.)
|
1.09091e+007 |
|
Qtrly Earnings Growth
|
-1 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-47 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.01 |
|
Price to Cash Flow
|
0.69 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
990150 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
